Baird Maintains an 'Outperform' on Pharmasset (VRUS); Delivering the Goods; Excellent SVR12 for '7977
Tweet Send to a Friend
Baird maintains an 'Outperform' on Pharmasset (NASDAQ: VRUS) price target raised from $73 to $88.
Baird analyst says, "Continue to ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Baird analyst says, "Continue to ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
